AstraZeneca: Lynparza Combo Recommended in EU for Prostate Cancer
2022年11月14日 - 4:44PM
Dow Jones News
By Kyle Morris
AstraZeneca PLC said Monday that a Lynparza combination has been
recommended for marketing authorization in the European Union for
the treatment of metastatic castration-resistant prostate
cancer.
The Anglo-Swedish pharma major said Lynparza in combination with
abiraterone and prednisone or prednisolone has been recommended by
the Committee for Medicinal Products for Human Use of the European
Medicines Agency for the treatment of adult patients for whom
chemotherapy isn't clinically indicated.
Write to Kyle Morris at kyle.morris@dowjones.com
(END) Dow Jones Newswires
November 14, 2022 02:29 ET (07:29 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
過去 株価チャート
から 3 2024 まで 4 2024
Astrazeneca (LSE:AZN)
過去 株価チャート
から 4 2023 まで 4 2024